Chrisomalis highlights Immuneering’s novel dual MEK inhibitor Atebimetinib, its potential to treat MAPK-driven tumors, strong clinical collaboration with Regeneron and Eli Lilly, and promising Phase 2a results in pancreatic cancer as key attractive factors.
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395657524/image_1395657524.jpg?io=getty-c-w750
Source link